Solventum (NYSE:SOLV) Cut to Buy at Wall Street Zen

Key Points

• Solventum (NYSE:SOLV) was downgraded from a "strong-buy" to a "buy" rating by Wall Street Zen, indicating a shift in analyst sentiment.
• Several brokerages have recently upgraded their ratings on Solventum, with price targets ranging from $79.00 to $103.00, reflecting a generally positive outlook on its stock performance.
• Solventum reported a quarterly EPS of $1.69, surpassing estimates, and its quarterly revenue increased by 3.8% year-over-year, suggesting financial growth despite mixed analyst ratings.

Solventum (NYSE:SOLV - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a note issued to investors on Tuesday.

Several other brokerages have also issued reports on SOLV. Piper Sandler restated an "overweight" rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. Argus upgraded shares of Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a report on Tuesday, July 1st. KeyCorp assumed coverage on shares of Solventum in a research note on Friday, June 6th. They set a "sector weight" rating on the stock. Finally, Wells Fargo & Company boosted their price target on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a research note on Friday, August 8th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $85.75.

Solventum Trading Up 2.6%

Shares of SOLV opened at $74.62 on Tuesday. Solventum has a 52-week low of $60.70 and a 52-week high of $85.92. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The firm's fifty day moving average is $73.50 and its two-hundred day moving average is $72.76. The stock has a market cap of $12.94 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 2.97 and a beta of 0.53.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 EPS for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same quarter in the previous year, the firm earned $1.56 EPS. The company's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts forecast that Solventum will post 6.58 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Solventum

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Orion Porfolio Solutions LLC grew its position in shares of Solventum by 0.7% during the second quarter. Orion Porfolio Solutions LLC now owns 24,295 shares of the company's stock worth $1,843,000 after buying an additional 176 shares in the last quarter. Thrivent Financial for Lutherans boosted its holdings in Solventum by 29.4% in the second quarter. Thrivent Financial for Lutherans now owns 12,332 shares of the company's stock valued at $934,000 after purchasing an additional 2,801 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Solventum in the second quarter valued at approximately $233,000. MRP Capital Investments LLC boosted its holdings in Solventum by 31.6% in the second quarter. MRP Capital Investments LLC now owns 15,200 shares of the company's stock valued at $1,153,000 after purchasing an additional 3,650 shares in the last quarter. Finally, State of Wyoming acquired a new position in Solventum in the second quarter valued at approximately $33,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.